ReviewACS omega2026
EGFR Mutations and Tyrosine Kinase Inhibitors: Structural Insights and Therapeutic Advances.
Review in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploring the Impact of Multiple Gene Mutations on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Response in Asian Nonsmall Cell Lung Cancer Patients.ACS pharmacology & translational science · 2026Review
- RLASON-CDR: a reinforcement learning-driven adaptive synergistic optimization network for cancer drug response prediction.Briefings in bioinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidermal Growth Factor Receptor (EGFR) mutations are a major driver of nonsmall cell lung cancer (NSCLC), particularly among nonsmoking populations. Oncogenic mutations within the tyrosine kinase (TK) domain of EGFR play a critical role in activating downstream signaling pathways that promote tumor growth and survival. Targeting this domain has proven effective in developing therapeutic agents for NSCLC. However, treatment with these inhibitors often leads to acquired resistance due to secondary on-target mutations and activation of alternative pathways, making disease management increasingly challenging and necessitating continuous development of novel drugs and strategies. This review provides a comprehensive structural analysis of EGFR, highlighting key activating and resistance-associated mutations and their implications for drug resistance. It also examines mutation-driven resistance mechanisms and the current landscape of novel tyrosine kinase inhibitors (TKIs) in clinical development.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.